Brain

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core TechnologiesJACKSON CENTER, Pa., Oct. 27, 2025…

3 months ago

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core TechnologiesJACKSON CENTER, Pa., Oct. 27, 2025…

3 months ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use…

3 months ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use…

3 months ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use…

3 months ago

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term…

3 months ago

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term…

3 months ago

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term…

3 months ago

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine…

3 months ago

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

Achieves significant expansion of NeurAxis’ total addressable marketClearance now includes patients aged “8 years and older”Expanded age indication will utilize…

3 months ago